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Abstract
Background: Granulocyte and monocyte adsorptive apheresis (GMA) has shown efficacy in patients with active
Crohn’s disease (CD). However, with routine weekly therapy, it may take several weeks to achieve remission. This
study was performed to assess clinical efficacy and safety of intensive GMA in patients with active CD.
Methods: In an open-label, prospective, randomized multicentre setting, 104 patients with CD activity index (CDAI)
of 200 to 450 received intensive GMA, at two sessions per week (n = 55) or one session per week (n = 49). Clinical
remission was defined as a CDAI score <150. Patients in each arm could receive up to 10 GMA sessions. However,
GMA treatment could be discontinued when CDAI decreased to <150 (clinical remission level).
Results: Of the 104 patients, 99 were available for efficacy evaluation as per protocol, 45 in the weekly GMA group,
and 54 in the intensive GMA group. Remission was achieved in 16 of 45 patients (35.6 %) in the weekly GMA and in
19 of 54 (35.2 %) in the intensive GMA (NS). Further, the mean time to remission was 35.4 ± 5.3 days in the weekly
GMA and 21.7 ± 2.7 days in the intensive GMA (P = 0.0373). Elevated leucocytes and erythrocyte sedimentation rate
were significantly improved by intensive GMA, from 8005/μL to 6950/μL (P = 0.0461) and from 54.5 mm/hr to 30.0
mm/hr (P = 0.0059), respectively. In both arms, GMA was well tolerated and was without safety concern.
Conclusions: In this study, with respect to remission rate, intensive GMA was not superior to weekly GMA, but the
time to remission was significantly shorter in the former without increasing the incidence of side effects. UMIN
registration # 000003666.
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Background
Biologics, such as anti-tumour necrosis factor (TNF)-α
antibodies or conventional medications with 5-aminosali
cylic acid, prednisolone, and immunomodulators like
azathioprine or 6-mercaptopurine are being used to treat
patients with active Crohn’s disease (CD) [1–6]. How-
ever, these drugs have often been associated with adverse
side effects that add to disease complexity [7–11].
Further, the anti-TNF infliximab is effective for induc-
tion and maintaining remission in patients with CD
[1, 12, 13], but more than 50 % of the patients may
show loss of response to this biologic over a 2 year
period [14]. Therefore, there is a need for effective
and well-tolerated treatment options for CD patients.
Granulocyte and monocyte adsorptive apheresis (GMA) is
an extracorporeal therapy that is performed with the
Adacolumn® (JIMRO, Takasaki, Japan). GMA select-
ively adsorbs elevated/activated granulocytes and mono-
cytes, and very few lymphocytes from the peripheral blood
[15]. A number of studies have reported on the thera-
peutic efficacy of GMA in patients with CD, ulcerative
colitis (UC) and generalized pustular psoriasis [16–21].
Additionally, GMA has shown efficacy in patients with
CD refractory to conventional medication [22, 23].
However, with the routinely applied weekly GMA, it
may take several weeks to see the treatment efficacy, be-
cause the Japan healthcare insurance covers only the one
GMA session per week regimen. With this in mind, we
hypothesized that an intensive course of GMA should
produce a more rapid efficacy compared with weekly
GMA as reported by Sakuraba, et al. for patients with
UC [24]. This prospective, randomized, multicenter
study was undertaken to evaluate the safety, efficacy,
and time to remission for intensive GMA, alongside the




This was an open-label, prospective, randomized, multi-
center study aimed at evaluating the clinical efficacy,
safety, and the appropriate treatment schedule for GMA
in patients with mild-to-moderately active CD. The
study was conducted at 31 medical institutions from
June 2010 to July 2014. Among the 31 study centers, 22
were academic, university institutes, 7 were municipal
hospital centers, and 2 were private community clinics.
All involved centers had adequate experience to under-
take GMA therapy for patients with inflammatory bowel
disease (IBD) (Additional file 1).
Patients
Male or non-pregnant female with a definitive diagnosis
of CD (12–75 years of age) were eligible if they had their
first CD episode or had relapsed with mild-to- moder-
ately active CD. The severity of CD was determined by
the Crohn’s disease activity index (CDAI) according to
Becktel et al. [25]. Patients who had a CDAI score of
200 to 450 were classified as having mild-to-moderately
active CD and were eligible. Disease location was to be
in the colon or in the ileum and the colon (ileocolic). Pa-
tients with granulocytopaenia (neutrophil count <2000
per μl), serious heart or kidney malfunction, coagulation
disorder, or had infection were to be excluded. Further,
patients who had started a corticosteroid within one
week, adalimumab within 2 weeks or infliximab within 6
weeks were excluded. Oral maintenance aminosalicylate
was allowed if it had been given at a stable dose for at
least 2 weeks before entry. This was at least 8 weeks for
azathioprine/6-mercaptopurine. Concomitant medica-
tions for diseases other than CD, which did not violate
the protocol inclusion criteria were allowed.
Allocations of patients to the study arms
After screening and enrollment for this study, patients
were randomly assigned to receive weekly GMA or re-
ceive intensive GMA, at two sessions per week in a 1:1
ratio. Randomization was done by a central computer-
generated randomization scheme that assigned the eli-
gible patient to a study centre.
GMA procedures
GMA treatment was done as previously described [16].
Briefly, the Adacolumns® and blood circuit lines were
primed with sterile saline to remove air bubbles from
the column void volume and flow lines. A second prim-
ing of the system was done with heparinized saline.
Blood access was through the antecubital vein in one
arm and from the column outflow, blood returned to
the patient via the antecubital vein in the contralateral
arm. The duration of one GMA session was 60 min at a
flow rate of 30 ml/min. Treatment was carried out partly
in an outpatient setting and partly in an inpatient set-
ting. Patients in the weekly GMA arm received one
GMA session per week and those in the intensive GMA
arm received two treatments sessions per week. The max-
imum number of GMA sessions allowed was 10. However,
when a patient achieved remission (CDAI <150), GMA
could be discontinued. The treatment and observation
time was 77 days in the weekly GMA and 42 days in the
intensive GMA.
Assessment of the treatment outcomes
With respect to the CD activity level, each patient was
evaluated by determining the CDAI score at screening,
baseline, and before each GMA session. The study pri-
mary end point was the rate of clinical remission defined
as CDAI <150. The secondary end point was the time to
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remission, a key measurement for comparison of inten-
sive GMA with weekly GMA. Evaluation of time to re-
mission was according to a life-table analysis by using
the Kaplan-Meier estimator graphs.
Ethical considerations
In Japan, GMA with the Adacolumn® is an officially ap-
proved treatment option for patients with IBD. However,
before initiating the GMA therapy, our study protocol
and patients’ informed consent forms were reviewed and
approved by the Institutional Review Board at each study
centre. Patients agreed to participate in this study after
being informed of the study purpose, actions of GMA
and the nature of the procedures involved. In case of an
under-age patient, consent from one of the patient’s par-
ents was sought. Written informed consent was obtained
from all patients. The study was conducted with strict
adherence to the Helsinki Declaration.
Statistical analysis
Data are presented as the mean ± SEM values or the
median with inter-quartile range. For statistical analysis,
data were processed by using a JMP software (version
10, SAS Institute, Cary, NC). Categorical data were ana-
lyzed by Fisher’s exact test, while continuous data were
evaluated by using the Wilcoxon-Mann–Whitney test or
as indicated otherwise in figure and table legends. P < 0.05
was considered statistically significant. The sample size
was determined as follows. This trial was designed as a su-
periority study. To show a statistical difference in the re-
mission rate between an assumption of a 30 % efficacy in
the weekly GMA and a 50 % efficacy in the intensive
GMA, with a first-kind error of 5 % and power of an 80 %,
a sample size of 93 patients per group in the per protocol
population was estimated. With approximately 5 % with-
drawal, a total of 100 patients had to be included in each
arm. However, when the patient number in each arm
reached around 50, an interim analysis was done, which
showed similar remission rates in the two arms. We then
decided to stop further patients enrollment and carried
out data analyses based on 104 patients.
Results
Patient randomization and demography
A total of 104 patients who were registered after screen-
ing were randomized to the weekly GMA arm (n = 49)
or to the intensive GMA arm (n = 55). Five patients in
the weekly GMA could not be included in the efficacy
analysis, two had not reached CDAI score ≥200 at
screening, one patient was not available for GMA ther-
apy and the remaining two patients were found to have
received GMA prior to assignment. Additionally, one
patient who was assigned to the intensive GMA arm had
received weekly GMA, this patient was included in the
weekly GMA arm during the analysis of the treatment
outcome (Fig. 1). Therefore, a total of 99 cases (45 in the
weekly GMA and 54 in the intensive GMA) were avail-
able for efficacy evaluations as per protocol. There was
no significant difference between the two groups with
respect to patients’ baseline demographic variables in-
cluding gender, age, CD duration, inpatient, outpatient,
CDAI score and disease location (Table 1). Concomitant
conventional pharmacological agents used by these pa-
tients included sulphasalazine, 5-aminosalicylic acid, pred-
nisolone, azathioprine, and 6-mercaptopurine. There was
no significant difference between the two groups with re-
spect to concomitant medications.
The primary efficacy outcome
As stated above, 45 of 49 patients randomized to the
weekly GMA arm and 54 of 55 patients randomized to
the intensive GMA arm were available for efficacy
Fig. 1 Patient disposition. CDAI = Crohn’s disease activity index; GMA = granulocyte and monocyte apheresis
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assessment as per protocol. During the 77 days of the
study period in the weekly GMA arm, 16 of 45 patients
(35.6 %) achieved clinical remission. Likewise, during the
42 days of the study period in the intensive GMA arm,
19 of 54 patients (35.2 %) achieved clinical remission,
not significantly different from the weekly GMA arm.
The secondary efficacy outcome
In Fig. 2, the Kaplan-Meier estimator graphs show
the cumulative remission rate in the weekly and the
intensive GMA arms. The mean time to remission
among the 16 patients in the weekly GMA who
achieved clinical remission was 35.4 ± 5.3 days, while
the mean time to remission in the 19 patients of the
intensive GMA arm who achieved remission was 21.7 ±
2.7 days (P = 0.0373). Therefore, in CD patients, intensive
GMA was associated with significantly more rapid remis-
sion as compared with the routinely applied weekly GMA.
Changes in leucocyte count, and inflammation markers
In spite of randomized assignment of enrolled pa-
tients, baseline leucocyte count (normal range: 4000–
9000/μL), erythrocyte sedimentation rate (ESR) (nor-
mal range: < 10 mm/hr (male); < 15 mm/hr (female))
and C-reactive protein (CRP) (normal range: < 0.3
mg/dL) concentration were found to be significantly
higher in the intensive GMA group compared with
the weekly GMA group, 8005/μL vs 7100/μL (P = 0.0273),
54.5 mm/hr vs 24.5 mm/hr (P = 0.0146) and 1.90 mg/dL
vs 0.90 mg/dL (P = 0.0478), respectively. However, only in
the intensive GMA group, leucocyte count (P = 0.0461)
and ESR (P = 0.0059) were significantly reduced. Likewise,
CRP level had decreased from 1.90 mg/dL to 0.80 mg/dL
(P = 0.0941). In the weekly GMA, CRP level was signifi-
cantly (P = 0.0277) decreased from 0.90 mg/dL at baseline
to 0.35 mg/dL (P = 0.0277), but, leucocyte count and ESR
level were not significantly affected (Table 2).
Treatment safety and tolerability
No device-related serious adverse event or unexpected ad-
verse event was observed in either group. Adverse events
were consistent with those generally observed during
extracorporeal procedures including transient headache,
dizziness, flushing, and pyrexia (Table 3). A total of 22 pa-
tients experienced none serious adverse events in the
weekly GMA (n = 11) and the intensive GMA (n = 11)
arms. In 5 of 11 patients in the weekly GMA and 6 of 11
patients in the intensive GMA, the adverse events were
considered to be likely treatment related. No episode of
opportunistic infection was observed in either group, sug-
gesting that therapeutic depletion of large numbers of leu-
cocytes by GMA might not lead to a weakened immune
function. Further, both intensive and weekly GMA treat-
ments were well tolerated by patients and there were no
technical problems.
Table 1 Baseline demographic variables of the 99 patients with active Crohn’s disease who were assigned to intensive GMA or to
weekly GMA in this study
Demography Intensive GMA Weekly GMA P value
(n = 54) (n = 45)
Male gender - n (%) 34 (63.0) 24 (53.3) 0.4133
Age, year 31.5 [24.8–40.5] 30.0 [23.5–43.0] 0.8965
Duration of disease, month 36.0 [5.5–138.0] 44.0 [11.5–93.0] 0.7081
Hospitalization - n (%) 27 (50.0) 22 (48.9) 1.0000
CDAI 260 [235–310] 259 [224–320] 0.9300
Disease location - n (%)
Colon 23 (42.6) 17 (37.8) 0.6838
Ileum and colon 31 (57.4) 28 (62.2) 0.6838
Surgical history – n (%) 13 (24.1) 15 (33.3) 0.3724
Previous biologics treatment - n (%) 10 (18.5) 10 (22.2) 0.8022
Concomitant medication - n (%)
5-Aminosalicylates 46 (85.2) 37 (82.2) 0.7865
Corticosteroids 8 (14.8) 8 (17.8) 0.7865
Azathioprine 7 (13.0) 9 (20.0) 0.4157
6-Mercaptopurine 3 (5.6) 2 (4.4) 1.0000
Nutrition therapy – n (%) 37 (68.5) 31 (68.9) 1.0000
Continuous variables are presented as the median [interquartile range] and were compared by the Wilcoxon-Mann–Whitney test. Categorical variables are
presented as patient’s number (%) and were compared by the Fisher’s exact test. CDAI, Chrohn’s disease activity index; GMA, granulocyte and monocyte
adsorptive apheresis
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Discussion
It has been reported that an intensive, two GMA session
per week produced a higher remission rate and in a
shorter time as compared with one GMA session per
week in patients with active UC [24]. In this study, we
found that intensive GMA as two sessions per week, up
to 10 sessions and weekly GMA, up to 10 sessions were
associated with similar remission rates in patients with
active CD, but time to remission was significantly better
with the former as compared with the latter. The mean
time to remission was 5 weeks in the weekly GMA vs 3
weeks in the intensive GMA. The obvious difference be-
tween the two treatment frequencies appears to be
shortening of morbidity time by intensive GMA.
Dignass et al. compared 5 and 10 GMA apheresis
treatments in steroid-refractory or steroid–dependent
UC patients, and reported that 5 GMA sessions were
not inferior to 10 sessions [26]. In their study protocol,
patients received 5 GMA treatments, once a week over 5
consecutive weeks, or 10 treatments, twice weekly for
the first 2 weeks followed by treatments once a week for
the following 6 consecutive weeks. Comparing our re-
sults with theirs, it might be important to conduct more
GMA treatments in a week to obtain a shorter time to
remission.
Leucocyte counts, ESR and CRP levels are known as
biomarkers of inflammation that correlate well with
disease activity in patients with IBD as well as in pa-
tients with other inflammatory diseases [27, 28]. In this
study, intensive GMA (but not weekly GMA) was asso-
ciated with a significant decrease in the elevated leuco-
cyte count, and ESR, reflecting amelioration of the
inflammation profile in the treated patients. Delayed
apoptosis (prolonged survival) and abnormal function
of neutrophils have been reported in patients with CD
[29, 30]. Neutrophils apoptosis is known to be an im-
portant event in the maintenance of immune homeo-
stasis [31]. However, endotoxin may be detectable
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Fig. 2 The Kaplan-Meier survival graphs showing cumulative
remission rates for patients who achieved clinical remission. In
the weekly GMA arm (dotted line), patients received one session
per week, while in the intensive arm (solid line), patients received two
GMA sessions per week. The mean time to remission for the 16
patients in the weekly GMA arm who achieved clinical remission
was 35.4 ± 5.3 days vs 21.7 ± 2.7 days in the 19 patients of the
intensive GMA arm who achieved clinical remission, P = 0.0373
by Wilcoxon-Mann–Whitney test. GMA = granulocyte and monocyte
adsorptive apheresis
Table 2 Changes in leucocyte count, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) following intensive and
weekly GMA in Crohn’s disease patients
Measurement Time point Intensive GMA Weekly GMA P value*, intensive vs weekly
Leucocyte (/μL) Baseline 8005 [6290–9378] 7100 [5340–7915] 0.0273
Post GMA 6950 [5400–8775] 7160 [5338–8465] 0.8601
P value**
Baseline vs Post GMA 0.0461 0.6260
ESR (mm/hr) Baseline 54.5 [37.0–68.0] 24.5 [9.7–52.5] 0.014
Post GMA 30.0 [10.5–51.5] 26.0 [7.0–47.0] 0.5480
P value**
Baseline vs Post GMA 0.0059 0.6553
CRP (mg/dL) Baseline 1.90 [0.60–4.05] 0.90 [0.40–2.62] 0.0478
Post GMA 0.80 [0.12–2.30] 0.35 [0.195–1.27] 0.4464
P value**
Baseline vs Post GMA 0.0941 0.0277
Data are represented as the median [interquartile range]
*Compared by Wilcoxon-Mann–Whitney test
**Compared by Wilcoxon-Signed-Rank test. GMA, granulocyte and monocyte adsorptive apheresis. For ESR, the number of patients at baseline in the intensive
and the weekly GMA arms were 22 and 24, respectively. Normal range: leucocyte 4000–9000/μL, CRP < 0.3 mg/dL, ESR < 10 mm/hr (male); < 15 mm/hr (female)
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neutrophils [32]. Additionally, an increased levels of
pro-inflammatory cytokines including granulocyte
macrophage colony-stimulating factor and macrophage
migration inhibitory factor are seen in patients with ac-
tive IBD [33, 34]. These mediators together with corti-
costeroids, which are given to most patients with active
IBD inhibit neutrophil apoptosis [35, 36]. These under-
standings support the notion that in patients with active
IBD, selective depletion of myeloid lineage leucocytes
(neutrophils and monocytes/macrophages) may induce
disease amelioration.
Further, Ishihara, et al. [37] reported that GMA with
the Adacolumn® induced neutrophil apoptosis during
passage of blood through the GMA column and expos-
ure of neutrophils to reactive oxygen species, which are
generated in the column. The authors reported ameli-
oration of induced colitis in animal models of IBD [37].
Similarly, the authors suggested that neutrophil apop-
tosis was induced via phagocytosis induced cell death
reaction in the column, and the apoptotic neutrophils
can be taken up by phagocytes including dendritic cells
and macrophages [38]. Finally, regulatory B cells
(Bregs) expanded in the model, and ameliorated colonic
inflammation [37]. Their results suggested that the
Adacolumn® not only selectively removes neutrophils
and monocytes from the circulation but also indirectly
promotes expansion of Bregs, which are involved in
maintaining regulatory T cells (Tregs) [39]. In clinical
settings, the Adacolumn® has been associated with ex-
pansion of Tregs, an increase in interleukin-10 level
and a decrease of anti-nuclear antibodies titer [40–42].
We were aware several limitations of this study. Firstly,
this was an open-label study and we did not use sham
columns in the weekly GMA group. More frequent pro-
cedures in the intensive GMA group may have affected
the results. Secondary, we evaluated the patients by the
CDAI, which is a subjective measurement. We did not
include objective inflammatory markers such as fecal
calprotectin as an inclusion criterion. Consequently,
some patients might have had minimal intestinal inflam-
mation despite their gastrointestinal symptoms at entry.
Thirdly, we did not perform any imaging evaluation such
as endoscopy, ultrasonography, and magnetic resonance
enterography in this study.
Table 3 Reported adverse events during the study
System organ class and preferred term Intensive GMA (N = 54) Weekly GMA (N = 45) Total
Nervous system disorder 8 (8.1)
Headache 2 (3.7) 5 (11.1)
Dizziness 1 (1.9) 0 (0.0)
General disorders and administration site condition 4 (4.0)
Pyrexia 2 (3.7) 1 (2.2)
Chest pain 1 (1.9) 0 (0.0)
Gastrointestinal disorders 2 (2.0)
Abdominal pain 0 (0.0) 1 (2.2)
Diarrhea 0 (0.0) 1 (2.2)
Cardiac disorders 2 (2.0)
Palpitations 1 (1.9) 0 (0.0)
Coldness/Bradycaridia 1 (1.9) 0 (0.0)
Musculoskeletal connective tissue disorders 2 (2.0)
Arthralgia 0 (0.0) 1 (2.2)
Myalgia 1 (1.9) 0 (0.0)
Vascular disorders 2 (2.0)
Hot flashes 0 (0.0) 1 (2.2)
Hypotension 1 (1.9) 0 (0.0)
Blood and lymphatic system disorders 1 (1.0)
Leukopenia 0 (0.0) 1 (2.2)
Ear and labyrinth disorders 1 (1.0)
Ear fullness 1 (1.9) 0 (0.0)
Total 11 (20.4) 11 (24.4) 22 (22.2)
Values are the patient’s number (%)
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Conclusion
In this study, applying intensive GMA to deplete ele-
vated and activated myeloid lineage leucocytes in pa-
tients with active CD resulted in a more rapid clinical
remission than weekly GMA, but without inducing an
increased remission rate. Therefore, in this study, with
respect to remission rate, intensive GMA was not super-
ior to weekly GMA, a shortening of the morbidity time
was the only obvious and clinically relevant benefit of
intensive GMA. Further, GMA is generally favored by
patients for its safety feature as well as for being a non-
pharmacologic treatment intervention.
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